Domain EYEION.com for sale! This premium domain is available now at Kadomain.com

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

  • medicalxpress.com language
  • 2025-09-07 15:50 event
  • 2 weeks ago schedule
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer
Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase II E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

834. Canada must protect youth from sports betting advertising, say specialists

  • 2 weeks ago schedule
  • medicalxpress.com language

Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal).

835. What actually happens in your brain when you change your mind?

  • 2 weeks ago schedule
  • medicalxpress.com language

Imagine a game show where the host asks the contestant to randomly pick one option out of three: A, B or C.

836. Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

  • 2 weeks ago schedule
  • medicalxpress.com language

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

837. First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

  • 2 weeks ago schedule
  • medicalxpress.com language

A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).

838. Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

  • 2 weeks ago schedule
  • medicalxpress.com language

Blood pressure matters at all ages. Children with higher blood pressure at age 7 may be at an increased risk of dying of cardiovascular disease by their mid-50s, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025, held in Baltimore, September 4–7, 2025.

839. AI helps older adults report accurate blood pressure readings at home

  • 2 weeks ago schedule
  • medicalxpress.com language

Artificial intelligence (AI) voice agents helped older adults with high blood pressure to accurately report their blood pressure readings and improved blood pressure management, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025 held in Baltimore, September 4–7, 2025.

840. What suicidal teens say matters most to them

  • 2 weeks ago schedule
  • medicalxpress.com language

Why would a suicidal teenager choose to live? It's not the kind of question most of us ever want to ask. Suicide is the third leading cause of death among 15–29-year-olds worldwide. Much of the research and media coverage still focuses on why teens might want to die. Far less often do we ask the opposite, equally urgent question: what makes life worth holding on to?

841. Intake of low-, no-calorie sweeteners tied to faster cognitive decline

  • 2 weeks ago schedule
  • medicalxpress.com language

Consumption of low- and no-calorie sweeteners (LNCSs) is associated with faster cognitive decline, according to a study published online Sept. 3 in Neurology.

842. Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

  • 2 weeks ago schedule
  • medicalxpress.com language

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

843. Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

  • 2 weeks ago schedule
  • medicalxpress.com language

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase II E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

844. Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC

  • 2 weeks ago schedule
  • medicalxpress.com language

Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.

845. Trial shows osimertinib plus chemotherapy improves overall survival in EGFR-mutated advanced NSCLC

  • 2 weeks ago schedule
  • medicalxpress.com language

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

846. Aumolertinib + chemotherapy improves progression-free survival in NSCLC: Clinical trial

  • 2 weeks ago schedule
  • medicalxpress.com language

New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations.

847. Can Florida really end vaccine mandates? What would this mean for the US and countries like Australia?

  • 2 weeks ago schedule
  • medicalxpress.com language

When it comes to the future of childhood immunizations, all eyes are on Robert F. Kennedy Jr, US Secretary of Health and Human Services, and his audacious attempt to discredit vaccinations with misinformation and dodgy "science."

848. Jamie Oliver is right—this is how much fruit and veg we really should be eating every day

  • 2 weeks ago schedule
  • medicalxpress.com language

Celebrity chef Jamie Oliver has stirred debate by calling the familiar five-a-day message "a lie". Speaking to the Times, he argued that the real health benefits of fruit and vegetables only start to add up at seven, eight or even 11 portions a day.

849. No, organ transplants won't make you live forever, whatever Putin says

  • 2 weeks ago schedule
  • medicalxpress.com language

What do world leaders talk about when they think we're not listening? This week it was the idea of living forever.

850. AI lung cancer risk model validated in predominantly Black population at hospital

  • 2 weeks ago schedule
  • medicalxpress.com language

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.

851. New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

  • 2 weeks ago schedule
  • medicalxpress.com language

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

852. Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

  • 2 weeks ago schedule
  • medicalxpress.com language

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.

Cookie Policy

We use cookies and similar technologies to help the site provide a better user experience. By using the website you agree to our Cookie Policy, Terms of Use and Privacy Policy.